A Canadian study found that TGFβ-dysregulated CAF ECM genes predict PD1/PDL1 resistance better than established biomarkers like the tumor mutation burden, cytolytic activity, T cell-inflamed signature, TGFβ expression alone, and the CAF signature (36). The gene discussed is CD274; the disease is neoplasm.